Auna S.A.AUNA
▼ NegativeCapitalrelevance
Adjusted EBITDA fell 9% due to margin pressure, talent investments, and Peru billing penalties, despite revenue growth.
Impact on stocks 1
Health Care
Auna S.A.Auna reported second-quarter results with revenue up 9% year over year on an FX-neutral basis, but adjusted EBITDA fell 9% amid margin pressure, talent investments and Peru billing penalties. Mexico patient volumes recovered, with surgeries up 7% sequentially and oncology chemotherapies and radiotherapies up 20% from the first quarter, while Colombia revenue rose 13% as the company expanded private-payer and risk-sharing contracts. Peru revenue increased 8%, though EBITDA was held flat by billing-related penalties and higher operating costs. Cash generation and leverage improved significantly: first-half operating cash flow rose 45%, free cash flow increased 181% and leverage declined to 3.6 times. Auna reaffirmed its outlook for roughly 12% FX-neutral revenue growth and adjusted EBITDA growth near the low end of its 10%-14% target range.
Auna S.A.Adjusted EBITDA fell 9% due to margin pressure, talent investments, and Peru billing penalties, despite revenue growth.